Abstract
Objective To estimate the potential risk and geographic range of Wuhan novel coronavirus (2019-nCoV) spread within and beyond China from January through to April, 2020.
Design Travel network-based modelling study.
Setting and participants General population travelling from Wuhan and other high-risk cities in China.
Main outcome measures Based on de-identified and aggregated mobile phone data, air passenger itinerary data, and case reports, we defined the relative importation risk and internal and international destinations of 2019-nCoV from Wuhan and other high-risk cities in China.
Results The cordon sanitaire of Wuhan is likely to have occurred during the latter stages of peak population numbers leaving the city before Lunar New Year (LNY), with travellers departing into neighbouring cities and other megacities in China, and a high proportion of cases likely travelled with symptoms at the early stage of the outbreak. Should secondary outbreaks occur in 17 high-risk secondary cities, they could contribute to seeding the virus in other highly connected cities within and beyond China after the LNY holiday. We estimated that 59,912 air passengers, of which 834 (95% UI: 478 - 1349) had 2019-nCoV infection, travelled from Wuhan to 382 cities outside of mainland China during the two weeks prior to Wuhan’s lockdown. The majority of these cities were in Asia, but major hubs in Europe, the US and Australia were also prominent, with strong correlation seen between predicted importation risks and reported cases seen. Because significant spread has already occurred, a large number of airline travellers (3.3 million under the scenario of 75% travel reduction from normal volumes) may be required to be screened at origin high-risk cities in China and destinations across the globe for the following three months of February to April, 2020 to effectively limit spread beyond its current extent.
Conclusion Further spread of 2019-nCoV within China and international exportation is likely to occur. All countries, especially vulnerable regions, should be prepared for efforts to contain the 2019-nCoV infection.
WHAT IS ALREADY KNOWN ON THIS TOPIC
The World Health Organization has declared the 2019-nCoV outbreak in China a Public Health Emergency of International Concern. Apparently originating from Wuhan, the virus has caused 20,530 confirmed cases across China, as of February 4th, 2020, and 153 cases reported in other 23 countries, as of February 3rd, 2020, with most having a travel history involving Wuhan.
Based on initial cases from Wuhan, 2019-nCoV has acquired human-to-human transmissibility, with an estimated basic reproductive number of 2.2 (95% confidence interval [CI]: 1.4 – 3.9). Transmission through asymptomatic contacts has also been reported.
According to Wuhan authorities, it is likely that more than five million residents had already left the city prior to the cordon sanitaire of the city that has been in place since January 23, 2020, just two days before the Lunar New Year (LNY). Where these travellers went and how high the risk of further spread of the virus within and beyond China is remains an open question.
WHAT THIS STUDY ADDS
Given the rapidly growing number of 2019-nCoV infections and limited understanding of the virus, we used spatio-temporally detailed domestic and international population movement data to infer the relative importation risk from Wuhan to secondary and tertiary cities across China before, during and after the LNY holiday.
We estimated the virus importation risk and potential destinations across the world from Wuhan and high-risk cities in mainland China during the LNY holiday and over the following three months.
The novel datasets from phones and travel itineraries used provide new insights on the impacts of internal and international connectivity on the ongoing and potential transmission of this emerging pathogen.
We explored various scenarios of travel restrictions and estimated the number of international airline travellers likely needing to be quarantined or screened to capture travellers potentially exposed to 2019-nCoV in high-risk cities of mainland China.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the grants from the Bill & Melinda Gates Foundation (OPP1134076); the European Union Horizon 2020 (MOOD 874850); the National Natural Science Fund of China (81773498, 71771213, 91846301); National Science and Technology Major Project of China (2016ZX10004222-009, 2018ZX10201001-010, 2018ZX10713001-007, 2017ZX10103009-005); Program of Shanghai Academic/Technology Research Leader (18XD1400300); Hunan Science and Technology Plan Project (2017RS3040, 2018JJ1034). AJT is supported by funding from the Bill & Melinda Gates Foundation (OPP1106427, OPP1032350, OPP1134076, OPP1094793), the Clinton Health Access Initiative, the UK Department for International Development (DFID) and the Wellcome Trust (106866/Z/15/Z, 204613/Z/16/Z). HY is supported by funding from the National Natural Science Fund for Distinguished Young Scholars of China (No. 81525023); Program of Shanghai Academic/Technology Research Leader (No. 18XD1400300); and the United States National Institutes of Health (Comprehensive International Program for Research on AIDS grant U19 AI51915). The research team members were independent from the funding agencies. The funders had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; and the preparation, review, or approval of the manuscript.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets on monthly air passenger data in February - April, 2018 used in this study are available from Dr. Kamran Khan (Kamran@bluedot.global). The case data are available from Dr. Shengjie Lai (Shengjie.Lai@soton.ac.uk). The datasets on holidays and air travel statistics from 2010 through 2018 used for validation are available on the WorldPop website (www.worldpop.org). The mobile phone datasets analysed during the current study are not publicly available since this would compromise the agreement with the data provider, but information on the process of requesting access to the data that support the findings of this study are available from Dr. Shengjie Lai (Shengjie.Lai@soton.ac.uk).